Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Cancer Immunotherapy Drug Discovery Outsourcing - Global Strategic Business Report 2026: Capitalize on 13.5% CAGR to $2.4 Billion by 2032 Featuring Covance, Crown Bioscience, Personalis and Promega

globenewswire.com
CDNS The article mentions AI and machine learning transforming drug discovery, which is a key area for Cadence's EDA tools. However, the company itself is not directly mentioned. SNPS The article discusses the role of AI and machine learning in drug discovery, a field where Synopsys's EDA tools are relevant. The company is not directly mentioned. ILMN The article highlights the importance of next-generation sequencing and multi-omics analysis in cancer immunotherapy drug discovery. Illumina is a key player in sequencing technology. REGN The article discusses the growth in cancer immunotherapy drug discovery outsourcing. Regeneron is a major player in this field, but not explicitly mentioned in the context of outsourcing. GILD The article focuses on the expanding market for cancer immunotherapy drug discovery outsourcing. Gilead is a significant biopharmaceutical company involved in this area. BMY The article discusses the growth of the cancer immunotherapy drug discovery outsourcing market. Bristol Myers Squibb is a major pharmaceutical company active in this therapeutic area. MRK The article details the expansion of the cancer immunotherapy drug discovery outsourcing market. Merck is a key pharmaceutical company involved in cancer immunotherapy research. PFE The article highlights the growth in cancer immunotherapy drug discovery outsourcing. Pfizer is a major pharmaceutical company with significant investments in this field. AZN The article discusses the expanding market for cancer immunotherapy drug discovery outsourcing. AstraZeneca is a prominent biopharmaceutical company in this sector. AMGN The article focuses on the growth of the cancer immunotherapy drug discovery outsourcing market. Amgen is a leading biotechnology company with a strong presence in this area. BIIB The article discusses the increasing demand for cancer immunotherapy drug discovery outsourcing. Biogen is a significant player in the biotechnology sector. VRTX The article highlights the growth in cancer immunotherapy drug discovery outsourcing. Vertex is a prominent biotechnology company, though not explicitly mentioned in relation to outsourcing. CRSP The article discusses the expanding market for cancer immunotherapy drug discovery outsourcing. CRISPR Therapeutics is a key player in gene editing technologies relevant to this field. EDIT The article focuses on the growth of cancer immunotherapy drug discovery outsourcing. Editas Medicine is involved in gene editing, which is relevant to advanced therapies. NTLA The article discusses the expanding market for cancer immunotherapy drug discovery outsourcing. Intellia Therapeutics is a leader in CRISPR-based gene editing therapies. EXAS The article mentions next-generation sequencing and multi-omics analysis in cancer immunotherapy drug discovery. Exact Sciences is a leader in genomic-based diagnostics. NVDA The article highlights the transformative role of AI and machine learning in drug discovery, areas where NVIDIA's GPUs are crucial for data analysis and model training. GOOG The article mentions AI and machine learning as key technologies transforming drug discovery. Google's AI capabilities are relevant to this trend. MSFT The article discusses the impact of AI and machine learning on drug discovery. Microsoft's cloud and AI services are relevant to this technological advancement. IBM The article mentions AI and machine learning transforming drug discovery. IBM has been investing in AI and healthcare solutions. PRGS Promega is listed as a featured company in the article about cancer immunotherapy drug discovery outsourcing, highlighting its participation in this market.

Cancer Immunotherapy Drug Discovery Outsourcing - Global Strategic Business Report 2026: Capitalize on 13.5% CAGR to $2.4 Billion by 2032 Featuring Covance, Crown Bioscience, Personalis and Promega Dublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "Cancer Immunotherapy Drug Discovery Outsourcing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

The global cancer immunotherapy drug discovery outsourcing market, valued at US$985.6 million in 2025, is projected to reach US$2.4 billion by 2032. The market is expected to expand at a compound annual growth rate of 13.5% between 2025 and 2032, supported by rising research and development costs, increasingly complex discovery programs, and growing demand for specialized scientific expertise.

Pharmaceutical companies, biotechnology firms, and research institutions are outsourcing target identification and validation, lead screening and optimization, biomarker discovery, cell-based assays, and preclinical testing to contract research organizations and specialist biotechnology providers. This strategy provides access to advanced research platforms, experienced scientific teams, and scalable infrastructure while helping organizations control costs and accelerate development timelines.

Outsourcing is particularly important for emerging biotechnology companies that are advancing innovative cancer immunotherapies without maintaining extensive internal discovery infrastructure. Partnerships with specialist providers support high-throughput screening, computational modeling, biomarker analysis, and translational research, enabling smaller organizations to compete more effectively and move promising candidates toward clinical development.

Technology Reshapes Cancer Immunotherapy Drug Discovery Outsourcing

Artificial intelligence, machine learning, next-generation sequencing, bioinformatics, and multi-omics analysis are transforming outsourced cancer immunotherapy research. AI-enabled platforms support large-scale data analysis, therapeutic target identification, response prediction, and lead optimization. These capabilities can improve candidate selection and reduce the risk of failure during preclinical development.

Next-generation sequencing is also strengthening tumor profiling, biomarker discovery, and personalized cancer immunotherapy development. CROs and bioinformatics specialists are integrating genomic, transcriptomic, proteomic, and other molecular datasets to provide deeper insights into tumor immunology. As pharmaceutical and biotechnology companies seek more precise therapeutic strategies, demand for outsourced providers with advanced data science and sequencing capabilities is expected to increase.

Global Partnerships Support Market Expansion

Globalization remains a major driver of the cancer immunotherapy drug discovery outsourcing market. China and India have become prominent outsourcing destinations due to their skilled scientific workforces, expanding biotechnology infrastructure, competitive operating costs, and capacity to support early-stage research and preclinical programs.

North America and Europe continue to play central roles in cancer immunotherapy innovation, supported by established CROs, pharmaceutical companies, biotechnology clusters, and academic research institutions. Cross-border partnerships allow sponsors to combine advanced scientific expertise with cost-efficient research capacity across multiple locations. This global model can support parallel development activities, improve operational flexibility, and shorten the path from discovery to clinical evaluation.

Market Growth Drivers

Segment and Regional Outlook

The report analyzes the market by drug type, service type, cancer type, and geography. Drug types include monoclonal antibodies, immunomodulators, oncolytic viral therapies and cancer vaccines, and other drug categories. Service segments include target identification and validation, lead screening and characterization, and cell-based assays. Cancer indications include lung, breast, prostate, melanoma, pancreatic, colorectal, and other cancer types.

Monoclonal antibodies are projected to reach US$910.3 million by 2032, advancing at a CAGR of 12.9%. The immunomodulators segment is forecast to grow at a CAGR of 14.4% during the analysis period.

The U.S. cancer immunotherapy drug discovery outsourcing market was valued at US$268.5 million in 2025. China is forecast to record a CAGR of 17.4% and reach US$509.8 million by 2032. The report also evaluates opportunities and market developments across Canada, Japan, Germany, the wider European market, Asia-Pacific, Latin America, the Middle East, and Africa.

Report Scope and Strategic Value

The study provides independent annual sales analysis and market forecasts in US$ million from 2025 through 2032. It examines competitive conditions, regional market structures, technology adoption, growth opportunities, and the strategic factors influencing outsourcing decisions.

Key questions addressed include:

Featured companies include Aquila Biomedical, BPS Biosciences Inc., Celentyx Ltd., Covance Inc., Crown Bioscience Inc., DiscoverX Corporation, Explicit Immuno-Oncology, Explicyte, GenScript Biotech Corporation, HD Biosciences Co. Ltd., Horizon Discovery Group PLC, ImmunXperts SA, Molecular Imaging Inc. (MI Bioresearch Inc.), Personalis Inc., Promega Corporation, and STC Biologics.

Domain Expert Insights

The analysis incorporates perspectives from experts across industry, enterprise, and academia, adding strategic context beyond conventional secondary research. The report tracks emerging shifts identified through expert discussions, corporate activity, scientific conferences, keynote presentations, panel sessions, institutional publications, annual reports, blogs, and validated company disclosures.

These intelligence sources are synthesized to identify the direction of the market, the forces influencing outsourcing strategies, and the developments most likely to affect investment and competitive positioning. The report also extends beyond market-level analysis to assess companies participating in and shaping the competitive environment.

Where analytically relevant, market share is examined at the regional level rather than represented solely through a single global figure. This approach reflects differences in competitive structures, research capabilities, service availability, and outsourcing practices across major geographic markets. Complimentary updates for one year provide ongoing visibility into significant market developments.

Key Attributes

For more information about this report visit https://www.researchandmarkets.com/r/qwag5v

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.